← Back to Search

Anticoagulant

Rivaroxaban for Heart Attack (R2MI Trial)

Phase 2 & 3
Waitlist Available
Led By Michelle Graham, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, estimated at 1-year
Awards & highlights

R2MI Trial Summary

This trial is testing whether a drug can help prevent major heart problems in people who have had a heart attack.

Eligible Conditions
  • Heart Attack

R2MI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, estimated at 1-year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, estimated at 1-year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility outcome
Secondary outcome measures
Number of participants who experience a composite of death, stroke or myocardial infarction
Number of participants who experience major bleeding

R2MI Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RivaroxabanActive Control1 Intervention
Rivaroxaban 2.5mg oral twice daily for 90-days
Group II: PlaceboPlacebo Group1 Intervention
Oral placebo tablet twice daily for 90-days

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
886 Previous Clinical Trials
384,770 Total Patients Enrolled
Michelle Graham, MDPrincipal InvestigatorUniversity of Alberta

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are the most that can join this clinical trial?

"That is correct. The clinicaltrials.gov website shows that this trial is currently recruiting patients. The trial was posted on April 5th, 2021 and was last updated on May 19th, 2022. The study is looking for 100 patients at 1 location."

Answered by AI

Is this research project novel in terms of its design or purpose?

"Rivaroxaban's journey through clinical trials began in 2015 with Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma sponsoring the first study. 2180 patients participated in the first Rivaroxaban trial, which resulted in the drug being approved for Phase 3 clinical trials. As of now, there are 61 active clinical trials for Rivaroxaban taking place in 402 cities and 45 countries."

Answered by AI

What indications does Rivaroxaban usually cover?

"Rivaroxaban is most often used as a treatment for venous thromboembolism, but it can also be given to patients suffering from deep vein thrombosis, chronic coronary artery disease, and cerebrovascular accident."

Answered by AI

Are patient applications being accepted at this time?

"The clinical trial is currently recruiting participants, with the original posting on 2021-04-05 and the most recent update on 2022-05-19."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Rivaroxaban in Type 2 Myocardial Infarctions
2021. "Rivaroxaban in Type 2 Myocardial Infarctions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04838808.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top